Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMAHEART: Semaglutide Mechanisms in Heart Failure
NCT06541509Phase 2Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of semaglutide in heart failure (HF), sponsored by University Medical Centre Ljubljana. Primary endpoints: Interleukin-6 at 4 months, Interleukin-8 at 4 months and 9 more. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06541509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541509.